In this Deep Dive Session, Prof. Laurie Sehn, a haematologist based at the British Colombia Cancer Center for Lymphoid Cancer, provides a comprehensive overview of the current landscape of Diffuse Large B-Cell Lymphoma (DLBCL) treatment. She discusses the importance of identifying high-risk patients, the role of genomic profiling, and the potential of immunotherapy approaches such as CAR-T cells and bispecific antibodies. Prof. Sehn also highlights the challenges of having two competing classification systems for lymphomas and emphasizes the need for patients’ specific biology to be examined by knowledgeable hematopathologists.
Haem Deep Dive
02-12-2024 Duffy-null Associated Neutrophil Count – Diagnostically Easy, Therapeutically Challenging
December 2, 2024
